Steven Joniau, MD, PhD, University Hospitals Leuven, Leuven, The Netherlands, discusses data from the Phase II ARNEO trial (NCT03080116) of neoadjuvant degarelix with or without apalutamide in patients with high-risk prostate cancer. 89 patients were randomized to either receive degarelix with apalutamide or a placebo and the difference in minimal residual disease was the primary endpoint. The cohort receiving degarelix and apalutamide achieved superior outcomes and loss of PTEN was additionally found to predict negative outcomes. This interview took place at the European Association of Urology (EAU) Meeting 2022.